Yuval Mika - 20 Jul 2023 Form 4 Insider Report for Orchestra BioMed Holdings, Inc. (OBIO)

Role: General Manager and Chief Technology Officer, Bioelectronic Therapies
Signature: /s/ Matthew R. Schob, Attorney-in-Fact
Issuer symbol: OBIO
Transactions as of: 20 Jul 2023
Net transactions value: $0
Form type: 4
Filing time: 24 Jul 2023, 17:10:39 UTC
Previous filing: 05 May 2023
Next filing: 10 May 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OBIO	Common Stock, par value $0.0001 per share ("Common Stock")	Award	$0	+40,000	+81%	$0.000000	89,572	20 Jul 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 34% of the shares will vest on the 18-month anniversary of the grant date, (ii) 33% the shares will vest on the two-year anniversary of the grant date, and (iii) 33% the shares will vest on the three-year anniversary of the grant date, subject to the Reporting Person's continuous service through such dates.

Content

Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 34% of the shares will vest on the 18-month anniversary of the grant date, (ii) 33% the shares will vest on the two-year anniversary of the grant date, and (iii) 33% the shares will vest on the three-year anniversary of the grant date, subject to the Reporting Person's continuous service through such dates.

Remarks:

General Manager and Chief Technology Officer, Bioelectronic Therapies